A novel amino acid agent could zero in on cancerous tumors and provide a much longer half-life than the status quo, according to a study published in the Journal of Nuclear Medicine.
The diversification of imaging agents is an important endeavor for the field of molecular medicine, as the limitations of FDG and the sensitivity and specificity of PET become increasingly clear. Researchers are looking to a range of new agents that work in very different ways to improve the mapping and staging of disease. Amino acid imaging is just one of these emerging techniques. Read more.